67856-23-9

Upstream product

• 38559-92-1 2-(4-Benzyloxyphenoxy)ethanoic acid 
• 205381-75-5 4-benzyloxyphenoxyethyl tetrahydro-2H-pyran-2-yl ether 
• 103-16-2 4-Benzyloxyphenol 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 3351-59-5 2-(4-benzyloxyphenoxy)ethyl bromide 
• 179019-78-4 2-(4-(benzyloxy)phenoxy)ethyl 4-methylbenzenesulfonate 
• 220698-59-9 p-(2-chloroethoxy)benzyloxybenzene 
• 220698-60-2 methyl 3,5-bis<2-(p-benzyloxyphenoxy)ethoxy>benzoate 
• 90414-53-2 5'-O-<2-<4-(benzyloxy)phenoxy>ethyl>thymidine 
• 13427-53-7 4-(2-hydroxyethoxy)-phenol 
• 1333171-25-7 1-(benzyloxy)-4-(2-iodoethoxy)benzene 
• 1333170-24-3 (6S)-6-{2-[4-benzyloxyphenoxy]ethoxy}-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 

Relevant academic research and scientific papers

PHENYL BENZYL ETHER DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF

Parts of compounds, after being labeled by radionuclide, of the phenyl benzyl ether derivative, are used as Aβ plaque imaging agent. The structural formula of the phenyl benzyl ether derivative is shown by formula (I). The present invention develops a kin

Preliminary evaluation of fluoro-pegylated benzyloxybenzenes for quantification of β-amyloid plaques by positron emission tomography

A new series of fluoro-pegylated benzyloxybenzenes were designed, synthesized and evaluated as PET probes for early detection of Aβ plaques. Molecular docking revealed that all of the flexible benzyloxybenzenes inserted themselves into the hydrophobic Val

Synthesis of N,N'-Bis(thioacetoxyalkoxy)piperazine and its self-assembled monolayer (SAM) formation on gold electrode

A novel terminal thioacetate-substitued alkoxy piperazine was successfully synthesized from 4-(benzyloxy)phenol after six-step reaction and employed as the surface-active material in fabrication of self-assembled monolayers (SAMs). Cyclic voltammetric (CV) results showed that the SAM-modified gold electrode had special capacity in recognition for Fe3+.

LTA4 Hydrolase inhibitors

The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

Synthesis of a new class of difunctional tetraphenylene crown ethers

Three new substituted tetraphenylene crown ethers have been made. Bis(5- carbomethoxy-1,3-phenylene)-bis(p-phenylene)-(3x + 6)-crown-x, where x = 12, 16, and 20 (11b-11d) were synthesized via [1 + 1] cyclization of methyl 3,5- bis[ω-chloro(oligoethyleneoxy)]benzoates (13b-3d) with methyl 3,5-bis[ω- (p-hydroxyphenoxy)(oligoethyleneoxy)]benzoates (16b-6d) using K2CO3 as base and tetrabutylammonium iodide as a phase transfer agent in dimethylformamide (DMF). The corresponding 30-membered (x = 8) macrocycle 11a could not be made by this approach; only the elimination product, 3,5-bis(vinyloxy)benzoic acid (19), was isolated. 16a-16d were made via alkylation of p-benzyloxyphenol (14) with 13a-13d, respectively, followed by hydrogenolysis with Pd/C as catalyst. No complexation of these macrocycles with dibenzylammonium ions was detected by NMR spectroscopy, but weak complexation of 11d with a paraquat derivative was observed.

Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi

Several drugs bearing the 4-phenoxyphenoxy skeleton and other closely related structures were designed, synthesized, and evaluated as antiproliferative agents against Trypanosoma cruzi, the etiologic agent of Chagas' disease. The new class of drugs was envisioned by modifying the nonpolar 4-phenoxyphenoxy moiety replacing selected aromatic protons by different groups via electrophilic aromatic substitution reactions as well as introducing a sulfur atom at file polar extreme. Of the designed compounds, sulfur-containing derivatives were shown to be potent antireplicative agents against T. cruzi. Among these drugs, 4-phenoxyphenoxyethyl thiocyanate (compound 56) proved to be an extremely active growth inhibitor of the epimastigote forms of T. cruzi and displayed an IC500 of 2.2 μM. Under the same assay conditions, this drug was much more active than Nifurtimox, one of the drugs currently in clinical use to control this disease. This thiocyanate derivative was also a very active inhibitor against the intracellular form of the parasite at the nanomolar level. Other sulfur derivatives prepared also exhibited very potent antiproliferative action against T. cruzi. The presence of a sulfur atom at the polar extreme for this family of compounds seems to be very important for biological action because this atom was always associated with high inhibition values. 4-Phenoxyphenoxyethyl thiocyanate presents very good prospective not only as a lead drug but also as a potential chemotherapeutic agent.

Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals

Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O) 2 NR 1 R 2 ] zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O) 2 NR 1 R 2 groups and is always at least one; R 1 and R 2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.

A reappraisal of the effect upon thymidine kinase of thymidine derivatives carrying large groups at the 5'-position

Several thymidine derivatives with hydrophobic 5'-substituents, linked by chemically stable amide and ether links, were synthesized as potential thymidine kinase inhibitors. None of these was active nor were several derivatives of thymidine 5'-acetate, wh

DERIVATIVES OF 1-PHENOXY-3-AMINO-PROPAN-2-OL

The present invention relates to new pharmacologically valuable derivatives of 1-phenoxy-3-amino-propan-2-ol having the formula STR1 wherein X denotes STR2 A denotes--CH 2--alkoxy,--O--alkoxyalkyl,--O--hydroxyalkyl or STR3 AN AROMATIC OR QUASI-AROMATIC, 5